Product Description
Pertuzumab is a monoclonal antibody that represents the first among a new class of agents known as human epidermal growth factor receptor (HER) dimerization inhibitors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23810292/)
Mechanisms of Action: EGFR Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified | Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Alopecia | Neutropenia | Anemia | Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified | Asthenia | Diarrhea
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Jordan, Kenya, Korea, Lebanon, Malaysia, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Uganda, United Arab Emirates, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 75
Highest Development Phases
Phase 3: Breast Cancer|Colorectal Cancer|Inflammatory Breast Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Prostate Cancer|Unilateral Breast Cancer
Phase 2: Bladder Cancer|Brain Cancer|Brain Stem Cancer|Central Nervous System Cancer|Meningeal Cancer|Non-Small-Cell Lung Cancer|Spinal Cord Cancer
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-003205-66 | P2 |
Active, not recruiting |
Breast Cancer |
2030-03-17 |
|
| EPIK-B2 | P3 |
Active, not recruiting |
Breast Cancer |
2030-02-07 |
|
| MEDOPP293 | P2 |
Unknown Status |
Breast Cancer |
2030-01-31 |
|
| D967UC00001 | P3 |
Unknown Status |
Breast Cancer |
2029-12-30 |